Contraceptive use in the Nordic countries

Acta Obstetricia et Gynecologica Scandinavica

Volumn 96, Issue 1, 2017, Pages 19-28

  Lindh, Ingela ^a   Skjeldestad, Finn E ^b   Gemzell Danielsson, Kristina ^c   Heikinheimo, Oskari ^d   Hognert, Helena ^a   Milsom, Ian ^a   Lidegaard, Øjvind ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Rigshospitalet   (Denmark)

Author keywords

Contraceptive use; hormonal contraception; intrauterine devices; long acting reversible contraception; oral contraceptives

Indexed keywords

ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTIMATE; POSTCOITUS CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CONTRACEPTIVE BEHAVIOR; COPPER INTRAUTERINE DEVICE; DENMARK; EUROPEAN MEDICINES AGENCY; FEMALE; FINLAND; HORMONAL CONTRACEPTION; HUMAN; ICELAND; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LOW DRUG DOSE; MIDDLE AGED; MIDWIFE; NORWAY; NURSE; ORAL CONTRACEPTION; ORAL CONTRACEPTIVE USE; PRESCRIPTIVE AUTHORITY; PRIORITY JOURNAL; SCANDINAVIA; SEXUAL EDUCATION; SWEDEN; VAGINA RING; YOUNG ADULT; CONDOM; EPIDEMIOLOGY; FACTUAL DATABASE; INTRAUTERINE CONTRACEPTIVE DEVICE; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ADULT; AGE FACTORS; CONDOMS; CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, ORAL, SYNTHETIC; CONTRACEPTIVES, POSTCOITAL; DATABASES, FACTUAL; FEMALE; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; MIDDLE AGED; SCANDINAVIAN AND NORDIC COUNTRIES; YOUNG ADULT;

EID: 85007490584     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.13055     Document Type: Article

References (30)

1. Wellings K. Trends in sexual behaviour. In: Glasier A, Wellings K, Critchley H (eds). Contraception and contraceptive use. London: RCOG Press, 2005. pp. 12–8.
2. ESHRE Capri Workshop Group. Non-contraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11:513–25.
3. United Nations. World Contraceptive Pattern 2013. Available online at: http://www.un.org/en/development/desa/population/publications/pdf/family/worldContraceptivePatternsWallChart2013.pdf (accessed October 2013).
4. NHS Contraceptive Services England, 2013–14. Available online at: http://www.hscic.gov.uk/catalogue/PUB15746/nhs-cont-serv-comm-cont-clin-eng-13-14-rep.pdf (accessed October 30, 2014).
5. Population and Societies September 2012. Available online at: https://www.ined.fr/fichier/s_rubrique/19160/pesa492.en.pdf (accessed September 2012).
6. Guttmacher Institute. Contraceptive use in the United States. 2016. Available online at: http://www.guttmacher.org/pubs/fb_contr_use.html (accessed September 2016).
7. Moreau C, Trussell J, Rodrigues G, Bajos N, Bouyer J. Contraceptive failure rate in France. Results from a population based survey. Hum Reprod. 2007;22:2422–7.
8. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.
9. Larsson M, Aneblom G, Odlind V, Tydén T. Reasons for pregnancy termination, contraceptive habits and contraceptive failure among Swedish women requesting an early pregnancy termination. Acta Obstet Gynecol Scand. 2002;81:64–71.
10. Kopp Kallner H, Thunell L, Brynhildsen J, Lindeberg M, Gemzell Danielsson K. Use of contraception and attitudes towards contraceptive use in Swedish women – a nationwide survey. PLoS ONE. 2015;10:e0125990.
11. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17:121–37.
12. Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thrombosis. Acta Obstet Gynecol Scand. 2012;91:769–78.
13. European Medicines Agency. Benefits of combined hormonal contraceptives (CHC) continue to outweigh risks – CHMP endorses PRAC recommendation. EMA/709120/2013. 2013. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001969.jsp&mid=WC0b01ac058004d5c1 (accessed November 22, 2013).
14. Cea Soriano L, Wallander MA, Andersson S, Filonenko A, Garcia Rodriguez LA. The continuation rates of long-acting reversible contraceptives in UK general practice using data from The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2015;24:52–8.
15. Bakken IJ, Skjeldestad FE, Schøyen U, Husby MG. Strong decline in female sterilization rates in Norway after the introduction of a new copayment system: a registry based study. BMC Womens Health. 2007;7:12.
16. Lindh I, Ellstrom AA, Blohm F, Milsom I. A longitudinal study of contraception and pregnancies in the same women followed for a quarter of a century. Hum Reprod. 2010;25:1415–22.
17. Jones J, Mosher WD, Daniels K. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. Natl Health Stat Report. 2012;60:1–25.
18. Wilson NM, Laursen M, Lidegaard Ö. Oral contraception in Denmark 1998–2010. Acta Obstet Gynecol Scand. 2012;91:810–5.
19. Cea Soriano L, Garcia Rodriguez LA, Machlitt A, Wallander MA. Use of prescription contraceptive methods in the UK general population: a primary care study. BJOG. 2014;121:53–60; discussion 60–1.
20. Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15–44: United States, 2011–2013. NCHS Data Brief. 2014;173:1–8.
21. Finer LF, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007–2009. Fertil Steril. 2012;98:893–7.
22. Haimovich S. Profile of long-acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care. 2009;14:187–95.
23. Josefsson A, Wiréhn A, Lindberg M, Foldemo A, Brynhilden J. Continuation rates of hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010. BMJ Open. 2013;3:e003401.
24. Wellings K, Jones KG, Mercer CH, Tanton C, Clifton S, Datta J, et al. The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet. 2013;382:1807–16.
25. Peipert JF, Madden T, Allsworth JE, Secure GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012;120:1291–7.
26. Roehr B. Free birth control cuts rates of unwanted pregnancies and abortions in the US. BMJ. 2012;345:e6763.
27. Cameron ST, Gordon R, Glasier A. The effect on use of making emergency contraception available free of charge. Contraception. 2012;86:366–9.
28. Pedersen W. Emergency contraception: why the absent effect on abortion rates? Acta Obstet Gynecol Scand. 2008;87:132–3.
29. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestagen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
30. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001–9. BMJ. 2011;343:d6423.